

28.02.2021

12:00 - 12:20 Workshop: How to write and peer review a manuscript / How to publish Channel: On demand

Moderation: L. Ellis¹, A.A. Adjei², ¹Surgical Oncology Dept., MD Anderson Cancer Center, Houston, US, ²Oncology Department, Mayo Clinic, Rochester, US

12:00 - 12:10 **How to write and peer review a manuscript / How to publish**

L. Ellis¹, A.A. Adjei², ¹MD Anderson Cancer Center, Houston, US, ²Mayo Clinic, Rochester, US

12:10 - 12:20 **How to write and peer review a manuscript / How to publish**

A.A. Adjei¹, L. Ellis², ¹Mayo Clinic, Rochester, US, ²MD Anderson Cancer Center, Houston, US

12:30 - 12:50 Workshop: How to choose a drug to study, biomarkers, etc Channel: On demand

Moderation: S. Bates¹, P. Lorusso², ¹Medicine Hematology/medical Oncology Department, Columbia University, New York, US, ²Medical Oncology, Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US

12:30 - 12:40 **How to choose a drug to study, biomarkers, etc**

P. Lorusso¹, S. Bates², ¹Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US, ²Columbia University, New York, US

12:40 - 12:50 **How to choose a drug to study, biomarkers, etc**

S. Bates¹, P. Lorusso², ¹Columbia University, New York, US, ²Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US

13:00 - 13:20 Workshop: How to write a grant Channel: On demand

Moderation: J. De Bono¹, G. Giaccone², ¹ICR - Institute of Cancer Research, London, GB, ²Oncology, Weill Cornell Medicine, New York, US

13:00 - 13:10 **How to write a grant**

J. De Bono¹, G. Giaccone², ¹ICR - Institute of Cancer Research, London, GB, ²Weill Cornell Medicine, New York, US

13:10 - 13:20 **How to write a grant**

G. Giaccone¹, J. De Bono², ¹Weill Cornell Medicine, New York, US, ²ICR - Institute of Cancer Research, London, GB

13:30 - 13:50 Workshop: How to assess response Channel: On demand

Moderation: L. Seymour¹, E. Calvo², E.G.E. De Vries³, ¹Ind Program, Canadian Cancer Trials Group, Kingston, CA, ²Dept. Early Clinical Drug Development, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ³Medical Oncology Department, UMCG - University Medical Center Groningen, Groningen, NL

13:30 - 13:40 Workshop: How to assess response

L. Seymour¹, E. Calvo², E.G.E. De Vries³, ¹Canadian Cancer Trials Group, Kingston, CA, ²Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ³UMCG - University Medical Center Groningen, Groningen, NL

14:00 - 14:20 Workshop: Challenges in conducting early clinical trials Channel: On demand

Moderation: R. Plummer¹, T. Yap², ¹Sir Bobby Robson Cancer Trials Research Centre, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ²Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, US

14:00 - 14:10 Challenges in conducting early clinical trials

T. Yap¹, R. Plummer², ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB

14:10 - 14:20 Challenges in conducting early clinical trials

R. Plummer¹, T. Yap², ¹The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ²The University of Texas M. D. Anderson Cancer Center, Houston, US

01.03.2021

08:00 - 20:00 ePoster Display Session

ePoster gallery

08:00 - 08:20 **Antibody-based therapies**

08:20 - 08:20 **1P - Is 177Lu-PSMA an effective treatment modality for mCRPC patients with visceral metastasis?**

M. Gupta, P. Choudhury, A. Singh, S. Rawal, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN

08:20 - 08:20 **2P - Molecular imaging evaluation of a novel Claudin18.2 specific monoclonal antibody labeled with radionuclide**

H. Zhu¹, J. Ding², X. Chong², C. Ji², C. Zhang², F. Teng³, Y. Gu³, X. Qian³, Z. Yang², L. Shen², J. Gao⁴, ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN, ³Mabspace Biosciences (Suzhou) Co. Ltd, Suzhou, CN, ⁴National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, CN

08:20 - 08:20 **3P - Determination of therapeutic effects of multifunctional micelle-based nanocarriers on breast cancer cells**

G. Ulu¹, N. Bayram², N. Abdulhadi¹, S. Gürdap², A. Işoğlu², S. Işoğlu², Y. Baran¹, ¹IYTE - Izmir Institute of Technology, Izmir, TR, ²Abdullah Gül University, Kayseri, TR

08:20 - 08:40 **Cell therapy**

08:40 - 08:40 **4P - Immunohybridoma cell-based vaccine for the treatment of patients with castration-resistant prostate cancer**

S. Hawlina¹, H. H. Chowdhury², M. Gabrijel², S. Trkov Bobnar², M. Kreft², G. Lenart¹, M. Cukjati³, A. Kopitar², A. Ihan², L. Ležaić¹, M. Gamek¹, A. Kmetec¹, M. Jeras⁴, R. Zorec², ¹University Medical Centre Ljubljana (UMCL), Ljubljana, SI, ²University of Ljubljana - Faculty of Medicine, Ljubljana, SI, ³Institute Service of Slovenia for Transfusion Medicine, Ljubljana, SI, ⁴University of Ljubljana - Faculty of Pharmacy, Ljubljana, SI

08:40 - 08:40 **5P - Anti-GD2 chimeric antigen receptor & TRAIL modified mesenchymal progenitors as novel strategy against Ewing’s sarcoma**

G. Golinelli¹, G. Grisendi², M. Dall'Ora², G. Casari², M. Prapa², C. Spano³, R. Talami², F. Banchelli², M. Dominici², ¹Università di Modena e Reggio Emilia, Modena, IT, ²University-Hospital of Modena and Reggio Emilia, Modena, IT, ³Rigenerand Srl, Medolla (MO), IT

08:40 - 09:00 **DNA damage repair**

- 09:00 - 09:00 **6P - AsiDNA targets drug-tolerant persister cells responsible of resistance to PARP inhibitors**
W. Jdey, V. Hayes, C. Doizelet, M.-C. Lienafa, V. Trochon-Joseph, J. Greciet, Onxeo, Paris, FR
- 09:00 - 09:20 **Epigenetics**
- 09:20 - 09:20 **9P - Predictive factors and profiles of tumour response to epigenetic drugs in phase I trials**
A. Procureur¹, A. Bizot², J.-M. Michot¹, S. Ammari¹, L. Verlingue¹, C. Baldini¹, P. Martin-Romano¹, V. Ribrag¹, J.-C. Soria¹, C. Massard³, S. Postel-Vinay¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Hopital Saint Louis AP-HP, Paris, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR
- 09:20 - 09:20 **10P - Emerging role of Telomeric repeat-containing RNA TERRA in hepatocellular carcinoma**
M. Manganelli¹, I. Grossi¹, J. Corsi², K. Juriková², E. Cusanelli², V. D'Agostino², S. Molino¹, G. Baiocchi¹, N. Portolani¹, A. Salvi¹, G. De Petro¹, ¹Università degli Studi di Brescia - Facoltà di Medicina e Chirurgia, Brescia, IT, ²University of Trento, Trento, IT
- 09:20 - 09:20 **11P - Convoluted role of H19 long non-coding RNA in regulating ICAM-1 and PVR in breast cancer patients**
A. Elkholy¹, R. Soliman², R. Youness², ¹GUC - German University in Cairo, 11759, EG, ²GUC - German University in Cairo, Cairo, EG
- 09:20 - 09:20 **12P - DNMT1/3-targeting microRNAs are over-expressed in the exosomes of estrogen-resistant breast cancer cells**
D. Sorokin¹, O. Andreeva², E. Mikhaevich¹, Y. Shchegolev³, V. Sigin⁴, V. Strelnikov⁵, A. Tanas⁵, A. Scherbakov², M. Krasil'nikov³, ¹Blokhin N.N. National Medical Research Center of Oncology, Moscow, RU, ²N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ³N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ⁴Federal State Budgetary Institution Research Centre for Medical Genetics, Moscow, RU, ⁵Research Centre for Medical Genetics, Moscow, RU
- 09:20 - 09:20 **13P - The role of long non-coding RNA RAMS11 in promoting colorectal cell development and metastasis**
M.Z. Islam Khan, H. Law, The Hong Kong Polytechnic University, Kowloon, HK
- 09:20 - 09:20 **14P - MALAT-1: A novel LncRNA modulating STAT-3 regulated cystathionine-#947;-lyase (CSE) in breast cancer**
N. Khater¹, D. Habashy², R. Youness², M.Z. Gad³, ¹GUC - German University in Cairo, New Cairo, EG, ²GUC - German University in Cairo, Cairo, EG, ³Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, EG

- 09:20 - 09:20 **15P - A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): Preliminary results**
R. Di Liello¹, C. Della Corte¹, V. Ciaramella¹, A. Insa², D. Compañ-Quilis², G. Alonso², R. Borrás², G. Viscardi¹, N. Zanaletti¹, F. Sparano¹, I. Cozzolino¹, M. Montella¹, G. Vicidomini¹, I. Pastor-Escartín², M. Santini¹, R. Franco¹, F. Ciardiello¹, P. Martín-Martorell², F. Morgillo¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Hospital Clínico Universitario de Valencia, Valencia, ES
- 09:20 - 09:20 **16P - How to translate what we learned from Gaucher's disease into new treatments for brain tumours**
C. Paret¹, R. Sandhoff², K. El Malki¹, K. Frauenknecht¹, A. Wingerter³, N. Vewinger¹, N. Lehmann³, J. Faber³, ¹University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, DE, ²DKFZ, Heidelberg, DE, ³University Medical Center of the Johannes Gutenberg-University Mainz, Magonza (Germany), DE
- 09:20 - 09:20 **17P - BCL6 and Notch pathway: A signaling axis leading to a novel druggable biotarget in triple-negative breast cancer**
F. De Santis¹, S. Romero-Cordoba², L. Castagnoli³, T. Volpari⁴, S. Faraci³, G. Fucà⁴, L. Cerchietti⁵, E. Tagliabue³, F. De Braud⁶, S. Pupa³, M. Di Nicola⁴, ¹Foundation IRCCS National Cancer Institute of Milan, Milan, IT, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MX, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁴Foundation IRCCS National Cancer Institute of Milan, Milan, IT, ⁵Weill Cornell Medical College, Cornell University, New York City, US, ⁶Istituto Nazionale dei Tumori, Milan, IT
- 09:20 - 09:20 **18P - Mutational landscape of metastatic lung squamous cell carcinoma associated with basal cell hyperplasia**
T. Gerashchenko¹, A. Schegoleva², A. Khozyainova², E. Rodionov², O. Pankova², V. Perelmuter², E. Denisov², ¹Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RU, ²Cancer Research Institute - Tomsk National Research Medical Center, Tomsk, RU
- 09:20 - 09:40 **Immunotherapy**
- 09:40 - 09:40 **20P - IGN002 (antiCD20-IFN γ 2b) intravenously administered tumour targeted delivery of IFN γ 2b and its effects in non-Hodgkin lymphoma**
S. Lakshmikanthan¹, P. Kolli¹, M. Tugnait¹, J. Dalsing-Hernandez², D. Diaz², P. Gonzales², F. Lebel¹, J. Barrett¹, ¹Spectrum Pharmaceuticals, Irvine, US, ²Translational Drug Development, Scottsdale, US
- 09:40 - 09:40 **21P - Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors**
P. Vlachostergios, Weill Cornell Medicine, New York, US
- 09:40 - 09:40 **22P - Toxicity profile of immune and non-immune therapies in phase I/II trials: A comprehensive longitudinal analysis**

L. Missri¹, P. Martin-Romano², C. Helissey³, E. Lanoy², C. Baldini², A. Varga², A. Hollebecque², J.-M. Michot², A. Gazzah², R. Bahleda², S. Champiat², A. Italiano⁴, V. Ribrag², E. Angevin⁵, J.-P. Armand², E. Deutsch², A. Marabelle², J.-C. Soria², C. Massard⁵, S. Postel-Vinay², ¹Universite Paris Sud, Orsay, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Bégin Military Teaching Hospital, Saint-Mandé, FR, ⁴Institut Bergonié, Bordeaux, FR, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR

09:40 - 09:40 **23P - Prediction of response to atezolizumab plus nab-paclitaxel in unresectable locally advanced triple-negative breast cancer (TNBC): The clinical usefulness of PD-L1 mRNA expression in plasma-derived exosomes**

L. Raimondi¹, F.M. Raimondi², R. Lazzeroni³, L. Di Benedetto⁴, G. Cimino⁵, G.P. Spinelli⁶, ¹Sapienza Università di Roma, Rome, IT, ²Biostatistical Consultant, Rome, IT, ³Sant'Andrea University Hospital, Rome, IT, ⁴BIOS SpA, Rome, IT, ⁵Sapienza University of Rome, Aprilia, IT, ⁶Oncologia Universitaria ASL Aprilia, Aprilia, IT

09:40 - 09:40 **24P - miR-17-5p: A potential activator of natural killer cells through tuning STAT3/H19/ULBP2 axis in breast cancer**

Y. Zeinelabdeen¹, R. Soliman², R. Youness², ¹GUC - German University in Cairo, New Cairo, EG, ²GUC - German University in Cairo, Cairo, EG

09:40 - 09:40 **25P - Promising immuno-oncological role of rosemary against breast cancer through altering miR-17-5p, MALAT-1, H19 and tumour microenvironment**

R. Soliman¹, R. Youness¹, H. Handoussa¹, M.Z. Gad², ¹GUC - German University in Cairo, Cairo, EG, ²Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, EG

09:40 - 09:40 **26P - Targeted photoimmunotherapy of tumour-specific nanomedicine for targeted triple-negative breast cancer therapy**

Y. Vellingiri, Bharathiar University, Coimbatore, IN

09:40 - 09:40 **27P - MiR-939-5p exhibits tumour suppressor activity and immune surveillance manipulation in triple-negative breast cancer**

H. Nafea¹, R. Youness², K. Abou-Aisha³, M.Z. Gad⁴, ¹Department of Biochemistry, Cairo, EG, ²GUC - German University in Cairo, Cairo, EG, ³German University in Cairo, Cairo, EG, ⁴Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, EG

09:40 - 09:40 **28P - Hijacking CCAT1/miR-17-5p axis alleviates immune checkpoint blockers resistance in PDL1+ TNBC patients**

N. Selem¹, H. Nafea², R. Youness³, M.Z. Gad¹, ¹Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, EG, ²Department of Biochemistry, Cairo, EG, ³GUC - German University in Cairo, Cairo, EG

09:40 - 09:40 **29P - Non-diploidy related prognostic molecular signature (NPMS) predict an immunologically hot phenotype in squamous cell lung cancer**

Z. Hu¹, H. Cui², K. Tan¹, J. Lee¹, ¹China-Japan Friendship Hospital, Beijing, CN, ²China-

Japan Friendship Hospital, Peking, CN

- 09:40 - 09:40 **30P - Protein signature associated with response and progression free survival in late-stage NSCLC patients treated with anti-PD-1 blockade**
E. Romano¹, K. Sklodowski², V. Dozio², A. Lanzós², K. Beeler², ¹Institut Curie, Paris, FR, ²Biognosys AG, Schlieren, CH
- 09:40 - 09:40 **31P - Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease: A UK tertiary cancer centre experience**
G. Patel¹, P. Sawhney¹, D. Ohana², M. Luong², Y.N.S. Wong¹, A. Lee³, M. Forster¹, ¹UCLH - University College London Hospitals NHS Foundation Trust, London, GB, ²University College London Hospitals NHS trust, London, GB, ³UCL Cancer Institute - Paul O'Gorman Building, London, GB
- 09:40 - 10:00 **Kinase-targeting agents**
- 10:00 - 10:00 **39P - Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: A phase Ib study in patients with advanced gastric cancer (RPT835GC1B)**
I. Tsimafeyeu¹, V. Kazey², N. Dragun³, D. Reznikov³, E. Gavrilova³, S. Gorbacheva², A. Nikiforova³, M. Byakhov⁴, S. Tjulandin⁵, ¹Institute of Oncology, Hadassah Medical Moscow, Moscow, RU, ²Exacte Labs, Moscow, RU, ³Ruspharmtech LLC, Saint-Petersburg, RU, ⁴Central Reutov Clinical Hospital, Reutov, RU, ⁵N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU
- 10:00 - 10:00 **40P - Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies**
J.S. Ho¹, V. Heong², W.P. Yong¹, R. Soo¹, C.E. Chee¹, A. Wong¹, Y.L. Thian¹, R. Sundar¹, A. Gopinathan¹, S.C. Lee¹, B.C. Goh¹, H. Xu³, D.S. Tan¹, ¹NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ²Tan Tock Seng Hospital, Singapore, SG, ³Karyopharm Therapeutics, Newton, US
- 10:00 - 10:00 **41P - The functional GRHL3-FLG axis predicts targeted therapy response in head and neck cancer**
Y. Bai¹, Z. Zhao², B. Denderen³, C. Darido³, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Tsinghua University, Beijing, CN, ³Peter MacCallum Cancer Center, Melbourne, AU
- 10:00 - 10:00 **42P - Using patient-reported outcomes (PROs) in phase I/II dose-finding oncology trials (DPOT): A global survey**
J. Lai-Kwon¹, A. Vanderbeek², A. Minchom¹, C. Yap³, ¹Institute of Cancer Research and the Royal Marsden Hospital, Sutton, GB, ²Institute of Cancer Research, Sutton, GB, ³ICR - The Institute of Cancer Research - North Site, Sutton, GB
- 10:00 - 10:00 **43P - Pre-clinical evaluation of potent and orally bioavailable next-generation**

inhibitors targeting the family of mutants that drive oncogenic BRAF dimer formation

Y.-C. Han¹, P.Y. Ng², R. Schulz¹, S.N. Yang¹, A. Lelo¹, L.S. Ogawa², M. O'Connor¹, N. Ishiyama², I. Jewett², D. Romashko¹, A. Salomatov², S. Thakur², S. Smith², E. Buck¹, C. Roberts², M. Lucas², T.-A. Lin¹, ¹Black Diamond Therapeutics, New York, US, ²Black Diamond Therapeutics, Cambridge, US

10:00 - 10:00 **44P - Investigation of Scorpion Venom-derived Anticancer Peptides Inhibit Metastatic Cancer Cells Growth and Induction of Apoptosis**

Y.-Q. Tang¹, T.N. Soon², ¹Taylor's University - Lakeside Campus, Subang Jaya, MY, ²SCHOOL OF BIOSCIENCES, SUBANG JAYA, MY

10:00 - 10:00 **45P - Antimetastatic activity of apigenin in human breast carcinoma cells by regulation of different MMPs gene expression**

S. Rajoriya, Nanaji Deshmukh Veterinary Science University,, Jabalpur, IN

10:00 - 14:15 **46P - ER α ; heterogeneous expression and the TGF- β RI status in the tumor predicted tamoxifen resistance**

N. Babyshkina¹, T. Dronova², S. Vtorushin¹, S. Patalyak¹, N. Cherdyntseva², ¹Tomsk National Research Medical Center, Russian Academy of Sciences Cancer Research Institute, Tomsk, RU, ²Tomsk National Research Medical Center, Russian Academy of Sciences Cancer Research Institute, National Research Tomsk State University, Tomsk, Russian Federation, Tomsk, RU

14:15 - 14:15 **47P - Evaluation of combinations of photoswitchable novel combretastatin A-4 analogues with chemotherapy drugs and metformin**

A. Scherbakov¹, D. Salnikova², A. Mikhailova¹, R. Balakhonov³, A. Yadykov³, V. Shirinian³, ¹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ²Lomonosov Moscow State University, Moscow, RU, ³N. D. Zelinsky Institute of Organic Chemistry, Moscow, RU

14:15 - 14:15 **48P - Target mining and drug repurposing for hepatocellular carcinoma via bioinformatic and computational approaches**

G. Nair¹, G.R. Saraswathy², G.N.S. Hema Sree², ¹M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ²M. S. Ramaiah University of Applied Sciences, Faculty of Pharmacy, Bangalore, IN

- 11:40 - 12:45 Welcome to TAT Virtual Congress 2021 & Keynote addresses** **Channel 1**
Moderation: R. Plummer¹, L. Seymour², J.-C. Soria³, ¹Sir Bobby Robson Cancer Trials Research Centre, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ²Ind Program, Canadian Cancer Trials Group, Kingston, CA, ³General Director, Institut Gustave Roussy, Villejuif, FR
- 11:40 - 11:45 **Live welcome to delegates**
J.-C. Soria¹, R. Plummer², L. Seymour³, ¹Institut Gustave Roussy, Villejuif, FR, ²The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ³Canadian Cancer Trials Group, Kingston, CA
- 11:45 - 11:50 **Introduction to the TAT 2020 Honorary award keynote lecture**
R. Plummer, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB
- 11:50 - 12:15 **TAT 2020 Honorary award keynote lecture: Rear view mirror and crystal ball of oncology drug development?**
L. Siu, Princess Margaret Cancer Centre, Toronto, CA
- 12:15 - 12:20 **Introduction to the TAT 2021 Honorary award keynote lecture**
L. Seymour, Canadian Cancer Trials Group, Kingston, CA
- 12:20 - 12:45 **TAT 2021 Honorary award keynote lecture: Academic drug discovery - Is partnership with industry a marriage made in heaven?**
R. Plummer, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB

13:00 - 14:15 Novel strategies in immuno-oncology Channel 1

Moderation: R. Plummer¹, J. Lopez², ¹Sir Bobby Robson Cancer Trials Research Centre, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ²Drug Development Unit, The Royal Marsden Hospital NHS Foundation Trust, Sutton, GB

13:00 - 13:20 **T-cell agonists**

S. Khleif, Georgetown University, Washington, US

13:20 - 13:40 **Personalising T-cell therapy by targeting clonal neoantigens**

J. Lopez, The Royal Marsden Hospital NHS Foundation Trust, Sutton, GB

13:40 - 14:00 **Senescence, senolytics and myeloid derived suppressor cells**

A. Alimonti, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

14:00 - 14:15 **Live Q&A and discussion**

A. Alimonti, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

- 13:00 - 14:15 Nothing is undruggable! Channel 2**
Moderation: J. Tabernero¹, S. Bates², ¹Medical Oncology Dept., Vall d'Hebron University Hospital, Barcelona, ES, ²Medicine Hematology/medical Oncology Department, Columbia University, New York, US
- 13:00 - 13:15 **Acoustic cluster therapy (ACT) as a mechanism of increasing drug delivery: Phase I experience**
U. Banerji, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB
- 13:15 - 13:30 **Proteosomal degradation as a mechanism to tackle difficult targets**
M. Barbacid, CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES
- 13:30 - 13:45 **Live Q&A and discussion**
S. Bates¹, J. Tabernero², U. Banerji³, M. Barbacid⁴, S. Postel-Vinay⁵, ¹Columbia University, New York, US, ²Vall d'Hebron University Hospital, Barcelona, ES, ³The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, ⁴CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES, ⁵Institut Gustave Roussy, Villejuif, FR
- 13:45 - 14:00 **Targeting SWI/SNF deficiency in solid tumours**
S. Postel-Vinay, Institut Gustave Roussy, Villejuif, FR
- 14:00 - 14:15 **Inhibiting protein translation**
S. Bates, Columbia University, New York, US

14:30 - 15:45 Cellular therapy for solid tumours Channel 1

Moderation: J.-C. Soria¹, K. Dhingra², ¹General Director, Institut Gustave Roussy, Villejuif, FR, ²KAPital Consulting LLC, New York, US

14:30 - 14:45 Innovative strategies CAR-T in solid tumors

M. Cobbold, AstraZeneca, Charlestown, US

14:45 - 15:00 Can CAR-T have efficacy in solid tumors?

S. Guedan, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES

15:00 - 15:15 PSMA targeted CAR-T therapy

B. Levine, University Of Pennsylvania, Philadelphia, US

15:15 - 15:30 Gamma delta T-cell therapeutics for treatment of solid tumors

L. Lamb, Incysus Therapeutics, Inc., Birmingham, US

15:30 - 15:45 Live Q&A and discussion

K. Dhingra¹, J.-C. Soria², M. Cobbold³, S. Guedan⁴, B. Levine⁵, L. Lamb⁶, ¹KAPital Consulting LLC, New York, US, ²Institut Gustave Roussy, Villejuif, FR, ³AstraZeneca, Charlestown, US, ⁴Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES, ⁵University Of Pennsylvania, Philadelphia, US, ⁶Incysus Therapeutics, Inc., Birmingham, US

- 14:30 - 15:45 Antibody-drug conjugate (ADC) technology** **Channel 2**
Moderation: G. Curigliano¹, N. Yamamoto², ¹Early Drug Development for Innovative Therapies Division, European Institute of Oncology, Milan, IT, ²Developmental Therapeutics Dept., National Cancer Center - Tsukiji Campus, Chuo-ku, JP
- 14:30 - 14:45 **Clinical development of next generation ADCs**
A. Tolcher, NEXT Oncology™, San Antonio, US
- 14:45 - 15:00 **Re-positioning the payload**
N. Yamamoto, National Cancer Center - Tsukiji Campus, Chuo-ku, JP
- 15:00 - 15:15 **ADCs and new targets in solid tumours**
G. Curigliano, European Institute of Oncology, Milan, IT
- 15:15 - 15:30 **Tumour-targeted immune-stimulating antibody conjugates (ISACs): A new class of immuno-oncology therapeutics**
S. Ackerman, Bolt Biotherapeutics, Redwood City, US
- 15:30 - 15:45 **Live Q&A and discussion**
G. Curigliano¹, N. Yamamoto², A. Tolcher³, S. Ackerman⁴, ¹European Institute of Oncology, Milan, IT, ²National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ³NEXT Oncology™, San Antonio, US, ⁴Bolt Biotherapeutics, Redwood City, US

- 16:00 - 17:15 Preclinical studies to identify effective combination therapies Channel 1**
Moderation: P. Bedard¹, P. Lorusso², ¹Princess Margaret Cancer Center, Toronto, CA, ²Medical Oncology, Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US
- 16:00 - 16:15 **AI augmented selection for drug combinations**
B. Al-Lazikani, The Institute of Cancer Research (Sutton Site), Sutton, GB
- 16:15 - 16:30 **The use of organoids as preclinical models**
E. Voest, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL
- 16:30 - 16:45 **CRISPR library and other screens for synthetic lethality**
R. Bernards, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 16:45 - 17:00 **Gastrointestinal cancer organoids for forward and reverse translation**
N. Valeri, The Institute of Cancer Research (Sutton), Sutton, GB
- 17:00 - 17:15 **Live Q&A and discussion**
P. Bedard¹, P. Lorusso², B. Al-Lazikani³, E. Voest⁴, R. Bernards⁵, N. Valeri⁶, ¹Princess Margaret Cancer Center, Toronto, CA, ²Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US, ³The Institute of Cancer Research (Sutton Site), Sutton, GB, ⁴Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁵The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁶The Institute of Cancer Research (Sutton), Sutton, GB

- 16:00 - 17:15 Where next with oncolytics? Channel 2**
Moderation: A.A. Adjei¹, L. Seymour², ¹Oncology Department, Mayo Clinic, Rochester, US, ²Ind Program, Canadian Cancer Trials Group, Kingston, CA
- 16:00 - 16:15 **Viro-immunotherapy and RNA-based oncolytic virotherapy**
A.A. Adjei, Mayo Clinic, Rochester, US
- 16:15 - 16:30 **Antibody armed oncolytic viruses**
E. Quemeneur, Transgene SA, Illkirch-Graffenstaden, FR
- 16:30 - 16:45 **Use of oncolytic peptides to overcome tumour heterogeneity**
Ø. Rekdal, Lytix Biopharma AS avd, Oslo, NO
- 16:45 - 17:00 **Oncolytics, radiation and other combinations**
K. Harrington, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB
- 17:00 - 17:15 **Live Q&A and discussion**
A.A. Adjei¹, L. Seymour², E. Quemeneur³, Ø. Rekdal⁴, K. Harrington⁵, ¹Mayo Clinic, Rochester, US, ²Canadian Cancer Trials Group, Kingston, CA, ³Transgene SA, Illkirch-Graffenstaden, FR, ⁴Lytix Biopharma AS avd, Oslo, NO, ⁵Institute of Cancer Research ICR, London, GB
- 17:30 - 18:40 Proffered Paper session Channel 1**
Moderation: D. Hyman¹, R. Plummer², C. Yap³, ¹Loxo Oncology, Inc., Stamford, US, ²Sir Bobby Robson Cancer Trials Research Centre, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ³Clinical Trials And Statistics Unit, ICR - The Institute of Cancer Research - North Site, Sutton, GB
- 17:30 - 17:40 **70 - Updated results from phase 1 study of CC-90011 in patients (pts) with solid tumors (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)**
A. Hollebecque¹, J. De Bono², S. Salvagni³, R. Plummer⁴, P. Niccoli⁵, J. Capdevila⁶, G. Curigliano⁷, V. Moreno⁸, F. De Braud⁹, S. Gonzalez De Villambrosía¹⁰, P. Martin-Romano¹, E. Baudin¹¹, M. Arias¹², J. De Alvaro¹², J. Parra-Palau¹², T. Sánchez-Pérez¹², I. Aronchik¹², E. Filvaroff¹³, M. Lamba¹³, Z. Nikolova¹⁴, ¹Institut Gustave Roussy, Villejuif, FR, ²ICR - Institute of Cancer Research, London, GB, ³Policlinico S. Orsola-Malpighi, Bologna, IT, ⁴The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ⁵Institut Paoli-Calmettes, Marseille, FR, ⁶Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁷European Institute of Oncology, Milan, IT, ⁸University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁹Istituto Nazionale dei Tumori, Milan, IT, ¹⁰Hospital Universitario Marqués de Valdecilla, Santander, ES, ¹¹Gustave Roussy - Cancer Campus, Villejuif, FR, ¹²Celgene, A Bristol-Myers Squibb Company, Summit, US, ¹³Bristol-Myers Squibb, Summit, US, ¹⁴Celgene International Switzerland, Boudry, CH

- 17:40 - 17:50 **320 - First-in-human (FIH) study of SCC244, a novel potent and highly selective c- MET inhibitor, in patients (pts) with Advanced non-small cell lung cancer (NSCLC)**
H. Chen¹, J.-J. Yang¹, J.-Y. Zhou², J. Zhao³, Y.-P. Sun⁴, Q. Wen⁴, Q. Zhou¹, Z. Zhang¹, H.-Y. Tu¹, J.-Y. Zhou², P. Zhang², X. Chen², H.-X. Chen³, Q. Dang⁴, M.-H. Sun⁵, Y. Li⁵, Y.-L. Wu¹,
¹Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ²The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, ³Peking University Cancer Hospital & Institute, Beijing, CN, ⁴Jinan Central Hospital Affiliated to Shandong University, Jinan, CN, ⁵Haihe Biopharma Co., Ltd, Shanghai, CN
- 17:50 - 18:00 **Invited discussant of abstracts 70 and 320**
J. Rodon, The University of Texas M. D. Anderson Cancer Center, Houston, US
- 18:00 - 18:05 **Live Q&A and discussion**
D. Hyman¹, C. Yap², R. Plummer³, J. Rodon⁴, A. Hollebecque⁵, H. Chen⁶, ¹Loxo Oncology, Inc., Stamford, US, ²ICR - The Institute of Cancer Research - North Site, Sutton, GB, ³The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ⁴The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN
- 18:05 - 18:15 **190 - Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumors and superficial lesions**
O. Hamid¹, M. Hellman², B. Carneiro³, T. Marron⁴, V. Subbiah⁵, I. Mehmi¹, J. Eyles⁶, V. Dubois⁷, B. Ridgway⁷, O. Hamid⁷, A. Gasco Hernandez⁷, ¹The Angeles Clinical and Research Institute, Los Angeles, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Brown University, Providence, US, ⁴Mount Sinai, New York, US, ⁵MD Anderson Cancer Center, Houston, US, ⁶AstraZeneca, Gaithersburg, US, ⁷AstraZeneca, Gaithersburg, US
- 18:15 - 18:25 **330 - A phase I study to evaluate safety, pharmacokinetics (PK), and preliminary efficacy of CYH33, a phosphatidylinositol 3-kinase α (PI3K α) inhibitor, in patients (pts) with advanced solid tumors**
X.L. Wei¹, J.-H. Liu², H. Zhao³, Y. Zhang², Q.-W. Liu², B.-Y. Zou², F. Wang², Z.-Q. Wang², M.-Z. Qiu², Q.-Q. Yu⁴, Y.-W. Du⁴, R.-H. Xu², ¹State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, CN, ²State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Guangzhou, CN, ³Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁴Haihe Biopharma Co., Ltd, Shanghai, CN
- 18:25 - 18:35 **Invited discussant of abstracts 190 and 330**
A. Tolcher, NEXT Oncology™, San Antonio, US
- 18:35 - 18:40 **Live Q&A and discussion**
D. Hyman¹, C. Yap², R. Plummer³, A. Tolcher⁴, X.L. Wei⁵, O. Hamid⁶, ¹Loxo Oncology,



Inc., Stamford, US, ²ICR - The Institute of Cancer Research - North Site, Sutton, GB, ³The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ⁴NEXT Oncology™, San Antonio, US, ⁵State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, CN, ⁶The Angeles Clinical and Research Institute, Los Angeles, US

18:40 - 19:00	Workshop Live Q&As in collaboration with the ESMO YOC: "How to write and peer review a manuscript / How to publish"	Channel 2
	Moderation: A.A. Adjei ¹ , L. Ellis ² , M. Lambertini ³ , ¹ Oncology Department, Mayo Clinic, Rochester, US, ² Surgical Oncology Dept., MD Anderson Cancer Center, Houston, US, ³ Genoa, IT	
19:10 - 19:30	Workshop Live Q&As in collaboration with the ESMO YOC: "How to choose a drug to study, biomarkers, etc"	Channel 2
	Moderation: S. Bates ¹ , P. Lorusso ² , E. Mariamidze ³ , ¹ Medicine Hematology/medical Oncology Department, Columbia University, New York, US, ² Medical Oncology, Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US, ³ Research Institute Of Clinical Medicine Todua Clinic, Tbilisi, GE	
19:40 - 20:00	Workshop Live Q&As in collaboration with the ESMO YOC: "How to write a grant"	Channel 2
	Moderation: G. Giaccone ¹ , J. De Bono ² , T. Amaral ³ , ¹ Oncology, Weill Cornell Medicine, New York, US, ² ICR - Institute of Cancer Research, London, GB, ³ University Hospital Tubingen, Tuebingen, DE	

02.03.2021

08:00 - 20:00 ePoster Display session

ePoster gallery

08:00 - 08:20 **Antibody-based therapies**

08:20 - 08:20 **1P - Is 177Lu-PSMA an effective treatment modality for mCRPC patients with visceral metastasis?**

M. Gupta, P. Choudhury, A. Singh, S. Rawal, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN

08:20 - 08:20 **2P - Molecular imaging evaluation of a novel Claudin18.2 specific monoclonal antibody labeled with radionuclide**

H. Zhu¹, J. Ding², X. Chong², C. Ji², C. Zhang², F. Teng³, Y. Gu³, X. Qian³, Z. Yang², L. Shen², J. Gao⁴, ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN, ³Mabspace Biosciences (Suzhou) Co. Ltd, Suzhou, CN, ⁴National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, CN

08:20 - 08:20 **3P - Determination of therapeutic effects of multifunctional micelle-based nanocarriers on breast cancer cells**

G. Ulu¹, N. Bayram², N. Abdulhadi¹, S. Gürdap², A. Işoğlu², S. Işoğlu², Y. Baran¹, ¹IYTE - Izmir Institute of Technology, Izmir, TR, ²Abdullah Gül University, Kayseri, TR

08:20 - 08:40 **Cell therapy**

08:40 - 08:40 **4P - Immunohybridoma cell-based vaccine for the treatment of patients with castration-resistant prostate cancer**

S. Hawlina¹, H. H. Chowdhury², M. Gabrijel², S. Trkov Bobnar², M. Kreft², G. Lenart¹, M. Cukjati³, A. Kopitar², A. Ihan², L. Ležaić¹, M. Gamek¹, A. Kmetec¹, M. Jeras⁴, R. Zorec², ¹University Medical Centre Ljubljana (UMCL), Ljubljana, SI, ²University of Ljubljana - Faculty of Medicine, Ljubljana, SI, ³Institute Service of Slovenia for Transfusion Medicine, Ljubljana, SI, ⁴University of Ljubljana - Faculty of Pharmacy, Ljubljana, SI

08:40 - 08:41 **5P - Anti-GD2 chimeric antigen receptor & TRAIL modified mesenchymal progenitors as novel strategy against Ewing’s sarcoma**

G. Golinelli¹, G. Grisendi², M. Dall'Ora², G. Casari², M. Prapa², C. Spano³, R. Talami², F. Banchelli², M. Dominici², ¹Università di Modena e Reggio Emilia, Modena, IT, ²University-Hospital of Modena and Reggio Emilia, Modena, IT, ³Rigenerand Srl, Medolla (MO), IT

08:41 - 08:41 **6P - AsiDNA targets drug-tolerant persister cells responsible of resistance to PARP inhibitors**

W. Jdey, V. Hayes, C. Doizelet, M.-C. Lienafa, V. Trochon-Joseph, J. Greciet, Onxeo, Paris,

FR

08:41 - 09:01 **DNA damage repair**

09:01 - 09:01 **9P - Predictive factors and profiles of tumour response to epigenetic drugs in phase I trials**

A. Procureur¹, A. Bizot², J.-M. Michot¹, S. Ammari¹, L. Verlingue¹, C. Baldini¹, P. Martin-Romano¹, V. Ribrag¹, J.-C. Soria¹, C. Massard³, S. Postel-Vinay¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Hopital Saint Louis AP-HP, Paris, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR

09:01 - 09:21 **Epigenetics**

09:21 - 09:21 **10P - Emerging role of Telomeric repeat-containing RNA TERRA in hepatocellular carcinoma**

M. Manganelli¹, I. Grossi¹, J. Corsi², K. Juriková², E. Cusanelli², V. D'Agostino², S. Molino¹, G. Baiocchi¹, N. Portolani¹, A. Salvi¹, G. De Petro¹, ¹Università degli Studi di Brescia - Facoltà di Medicina e Chirurgia, Brescia, IT, ²University of Trento, Trento, IT

09:21 - 09:21 **11P - Convoluted role of H19 long non-coding RNA in regulating ICAM-1 and PVR in breast cancer patients**

A. Elkholy¹, R. Soliman², R. Youness², ¹GUC - German University in Cairo, 11759, EG, ²GUC - German University in Cairo, Cairo, EG

09:21 - 09:21 **12P - DNMT1/3-targeting microRNAs are over-expressed in the exosomes of estrogen-resistant breast cancer cells**

D. Sorokin¹, O. Andreeva², E. Mikhaevich¹, Y. Shchegolev³, V. Sigin⁴, V. Strelnikov⁵, A. Tanas⁵, A. Scherbakov², M. Krasil'nikov³, ¹Blokhin N.N. National Medical Research Center of Oncology, Moscow, RU, ²N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ³N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ⁴Federal State Budgetary Institution Research Centre for Medical Genetics, Moscow, RU, ⁵Research Centre for Medical Genetics, Moscow, RU

09:21 - 09:21 **13P - The role of long non-coding RNA RAMS11 in promoting colorectal cell development and metastasis**

M.Z. Islam Khan, H. Law, The Hong Kong Polytechnic University, Kowloon, HK

09:21 - 09:21 **14P - MALAT-1: A novel LncRNA modulating STAT-3 regulated cystathionine- γ -lyase (CSE) in breast cancer**

N. Khater¹, D. Habashy², R. Youness², M.Z. Gad³, ¹GUC - German University in Cairo, New Cairo, EG, ²GUC - German University in Cairo, Cairo, EG, ³Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, EG

- 09:21 - 09:21 **15P - A pivotal multicenter translational research project on malignant pleural mesothelioma (MPM): Preliminary results**
R. Di Liello¹, C. Della Corte¹, V. Ciaramella¹, A. Insa², D. Compañ-Quilis², G. Alonso², R. Borrás², G. Viscardi¹, N. Zanaletti¹, F. Sparano¹, I. Cozzolino¹, M. Montella¹, G. Vicidomini¹, I. Pastor-Escartín², M. Santini¹, R. Franco¹, F. Ciardiello¹, P. Martín-Martorell², F. Morgillo¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Hospital Clínico Universitario de Valencia, Valencia, ES
- 09:21 - 09:21 **16P - How to translate what we learned from Gaucher's disease into new treatments for brain tumours**
C. Paret¹, R. Sandhoff², K. El Malki¹, K. Frauenknecht¹, A. Wingerter³, N. Vewinger¹, N. Lehmann³, J. Faber³, ¹University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, DE, ²DKFZ, Heidelberg, DE, ³University Medical Center of the Johannes Gutenberg-University Mainz, Magonza (Germany), DE
- 09:21 - 09:21 **17P - BCL6 and Notch pathway: A signaling axis leading to a novel druggable biotarget in triple-negative breast cancer**
F. De Santis¹, S. Romero-Cordoba², L. Castagnoli³, T. Volpari⁴, S. Faraci³, G. Fucà⁴, L. Cerchietti⁵, E. Tagliabue³, F. De Braud⁶, S. Pupa³, M. Di Nicola⁴, ¹Foundation IRCCS National Cancer Institute of Milan, Milan, IT, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MX, ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁴Foundation IRCCS National Cancer Institute of Milan, Milan, IT, ⁵Weill Cornell Medical College, Cornell University, New York City, US, ⁶Istituto Nazionale dei Tumori, Milan, IT
- 09:21 - 09:21 **18P - Mutational landscape of metastatic lung squamous cell carcinoma associated with basal cell hyperplasia**
T. Gerashchenko¹, A. Schegoleva², A. Khozyainova², E. Rodionov², O. Pankova², V. Perelmuter², E. Denisov², ¹Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RU, ²Cancer Research Institute - Tomsk National Research Medical Center, Tomsk, RU
- 09:21 - 09:21 **20P - IGN002 (antiCD20-IFN γ 2b) intravenously administered tumour targeted delivery of IFN γ 2b and its effects in non-Hodgkin lymphoma**
S. Lakshmikanthan¹, P. Kolli¹, M. Tugnait¹, J. Dalsing-Hernandez², D. Diaz², P. Gonzales², F. Lebel¹, J. Barrett¹, ¹Spectrum Pharmaceuticals, Irvine, US, ²Translational Drug Development, Scottsdale, US
- 09:21 - 09:41 **Immunotherapy**
- 09:41 - 09:41 **21P - Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors**
P. Vlachostergios, Weill Cornell Medicine, New York, US
- 09:41 - 09:41 **22P - Toxicity profile of immune and non-immune therapies in phase I/II trials: A**

comprehensive longitudinal analysis

L. Missri¹, P. Martin-Romano², C. Helissey³, E. Lanoy², C. Baldini², A. Varga², A. Hollebecque², J.-M. Michot², A. Gazzah², R. Bahleda², S. Champiat², A. Italiano⁴, V. Ribrag², E. Angevin⁵, J.-P. Armand², E. Deutsch², A. Marabelle², J.-C. Soria², C. Massard⁵, S. Postel-Vinay², ¹Universite Paris Sud, Orsay, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Bégin Military Teaching Hospital, Saint-Mandé, FR, ⁴Institut Bergonié, Bordeaux, FR, ⁵Gustave Roussy - Cancer Campus, Villejuif, FR

09:41 - 09:41 **23P - Prediction of response to atezolizumab plus nab-paclitaxel in unresectable locally advanced triple-negative breast cancer (TNBC): The clinical usefulness of PD-L1 mRNA expression in plasma-derived exosomes**

L. Raimondi¹, F.M. Raimondi², R. Lazzeroni³, L. Di Benedetto⁴, G. Cimino⁵, G.P. Spinelli⁶, ¹Sapienza Università di Roma, Rome, IT, ²Biostatistical Consultant, Rome, IT, ³Sant'Andrea University Hospital, Rome, IT, ⁴BIOS SpA, Rome, IT, ⁵Sapienza University of Rome, Aprilia, IT, ⁶Oncologia Universitaria ASL Aprilia, Aprilia, IT

09:41 - 09:41 **24P - miR-17-5p: A potential activator of natural killer cells through tuning STAT3/H19/ULBP2 axis in breast cancer**

Y. Zeinelabdeen¹, R. Soliman², R. Youness², ¹GUC - German University in Cairo, New Cairo, EG, ²GUC - German University in Cairo, Cairo, EG

09:41 - 09:41 **25P - Promising immuno-oncological role of rosemary against breast cancer through altering miR-17-5p, MALAT-1, H19 and tumour microenvironment**

R. Soliman¹, R. Youness¹, H. Handoussa¹, M.Z. Gad², ¹GUC - German University in Cairo, Cairo, EG, ²Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, EG

09:41 - 09:41 **26P - Targeted photoimmunotherapy of tumour-specific nanomedicine for targeted triple-negative breast cancer therapy**

Y. Vellingiri, Bharathiar University, Coimbatore, IN

09:41 - 09:41 **27P - MiR-939-5p exhibits tumour suppressor activity and immune surveillance manipulation in triple-negative breast cancer**

H. Nafea¹, R. Youness², K. Abou-Aisha³, M.Z. Gad⁴, ¹Department of Biochemistry, Cairo, EG, ²GUC - German University in Cairo, Cairo, EG, ³German University in Cairo, Cairo, EG, ⁴Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, EG

09:41 - 09:41 **28P - Hijacking CCAT1/miR-17-5p axis alleviates immune checkpoint blockers resistance in PDL1+ TNBC patients**

N. Selem¹, H. Nafea², R. Youness³, M.Z. Gad¹, ¹Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, EG, ²Department of Biochemistry, Cairo, EG, ³GUC - German University in Cairo, Cairo, EG

09:41 - 09:41 **29P - Non-diploidy related prognostic molecular signature (NPMS) predict an immunologically hot phenotype in squamous cell lung cancer**

Z. Hu¹, H. Cui², K. Tan¹, J. Lee¹, ¹China-Japan Friendship Hospital, Beijing, CN, ²China-Japan Friendship Hospital, Peking, CN

- 09:41 - 09:41 **30P - Protein signature associated with response and progression free survival in late-stage NSCLC patients treated with anti-PD-1 blockade**
E. Romano¹, K. Sklodowski², V. Dozio², A. Lanzós², K. Beeler², ¹Institut Curie, Paris, FR, ²Biognosys AG, Schlieren, CH
- 09:41 - 09:41 **31P - Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease: A UK tertiary cancer centre experience**
G. Patel¹, P. Sawhney¹, D. Ohana², M. Luong², Y.N.S. Wong¹, A. Lee³, M. Forster¹, ¹UCLH - University College London Hospitals NHS Foundation Trust, London, GB, ²University College London Hospitals NHS trust, London, GB, ³UCL Cancer Institute - Paul O'Gorman Building, London, GB
- 09:41 - 09:41 **39P - Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: A phase Ib study in patients with advanced gastric cancer (RPT835GC1B)**
I. Tsimafeyeu¹, V. Kazey², N. Dragun³, D. Reznikov³, E. Gavrilova³, S. Gorbacheva², A. Nikiforova³, M. Byakhov⁴, S. Tjulandin⁵, ¹Institute of Oncology, Hadassah Medical Moscow, Moscow, RU, ²Exacte Labs, Moscow, RU, ³Ruspharmtech LLC, Saint-Petersburg, RU, ⁴Central Reutov Clinical Hospital, Reutov, RU, ⁵N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU
- 09:41 - 10:01 **Kinase-targeting agents**
- 10:01 - 10:01 **40P - Phase I study of the safety, pharmacokinetics and pharmacodynamics of escalating doses followed by dose expansion of selinexor in Asian patients with advanced solid tumour malignancies**
J.S. Ho¹, V. Heong², W.P. Yong¹, R. Soo¹, C.E. Chee¹, A. Wong¹, Y.L. Thian¹, R. Sundar¹, A. Gopinathan¹, S.C. Lee¹, B.C. Goh¹, H. Xu³, D.S. Tan¹, ¹NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ²Tan Tock Seng Hospital, Singapore, SG, ³Karyopharm Therapeutics, Newton, US
- 10:01 - 10:01 **41P - The functional GRHL3-FLG axis predicts targeted therapy response in head and neck cancer**
Y. Bai¹, Z. Zhao², B. Denderen³, C. Darido³, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Tsinghua University, Beijing, CN, ³Peter MacCallum Cancer Center, Melbourne, AU
- 10:01 - 10:01 **42P - Using patient-reported outcomes (PROs) in phase I/II dose-finding oncology trials (DPOT): A global survey**
J. Lai-Kwon¹, A. Vanderbeek², A. Minchom¹, C. Yap³, ¹Institute of Cancer Research and the Royal Marsden Hospital, Sutton, GB, ²Institute of Cancer Research, Sutton, GB, ³ICR - The Institute of Cancer Research - North Site, Sutton, GB

- 10:01 - 10:01 **43P - Pre-clinical evaluation of potent and orally bioavailable next-generation inhibitors targeting the family of mutants that drive oncogenic BRAF dimer formation**
Y.-C. Han¹, P.Y. Ng², R. Schulz¹, S.N. Yang¹, A. Lelo¹, L.S. Ogawa², M. O'Connor¹, N. Ishiyama², I. Jewett², D. Romashko¹, A. Salomatov², S. Thakur², S. Smith², E. Buck¹, C. Roberts², M. Lucas², T.-A. Lin¹, ¹Black Diamond Therapeutics, New York, US, ²Black Diamond Therapeutics, Cambridge, US
- 10:01 - 10:01 **44P - Investigation of Scorpion Venom-derived Anticancer Peptides Inhibit Metastatic Cancer Cells Growth and Induction of Apoptosis**
Y.-O. Tang¹, T.N. Soon², ¹Taylor's University - Lakeside Campus, Subang Jaya, MY, ²SCHOOL OF BIOSCIENCES, SUBANG JAYA, MY
- 10:01 - 10:01 **45P - Antimetastatic activity of apigenin in human breast carcinoma cells by regulation of different MMPs gene expression**
S. Rajoriya, Nanaji Deshmukh Veterinary Science University,, Jabalpur, IN
- 10:01 - 14:16 **46P - ER α ; heterogeneous expression and the TGF- β RI status in the tumor predicted tamoxifen resistance**
N. Babushkina¹, T. Dronova², S. Vtorushin¹, S. Patalyak¹, N. Cherdyntseva², ¹Tomsk National Research Medical Center, Russian Academy of Sciences Cancer Research Institute, Tomsk, RU, ²Tomsk National Research Medical Center, Russian Academy of Sciences Cancer Research Institute, National Research Tomsk State University, Tomsk, Russian Federation, Tomsk, RU
- 14:16 - 14:16 **47P - Evaluation of combinations of photoswitchable novel combretastatin A-4 analogues with chemotherapy drugs and metformin**
A. Scherbakov¹, D. Salnikova², A. Mikhailova¹, R. Balakhonov³, A. Yadykov³, V. Shirinian³, ¹N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ²Lomonosov Moscow State University, Moscow, RU, ³N. D. Zelinsky Institute of Organic Chemistry, Moscow, RU
- 14:16 - 14:16 **48P - Target mining and drug repurposing for hepatocellular carcinoma via bioinformatic and computational approaches**
G. Nair¹, G.R. Saraswathy², G.N.S. Hema Sree², ¹M. S. Ramaiah University of Applied Sciences, Bangalore, IN, ²M. S. Ramaiah University of Applied Sciences, Faculty of Pharmacy, Bangalore, IN

11:45 - 12:15 ePoster chat session ePoster gallery

- 11:45 - 12:15 **Authors will answer your questions!**
N. Person, The Royal Marsden Hospital NHS Foundation Trust, London, GB

- 12:15 - 12:45** **Keynote lecture: What is the model for efficient drug development in the pharmaceutical industry?** **Channel 1**
Moderation: J.-C. Soria, General Director, Institut Gustave Roussy, Villejuif, FR
- 12:15 - 12:20 **Introduction**

J.-C. Soria, Institut Gustave Roussy, Villejuif, FR
- 12:20 - 12:45 **What is the model for efficient drug development in the pharmaceutical industry?**
D. Hyman, Loxo Oncology, Inc., Stamford, US
- 13:00 - 14:15** **Microbiome: Moving beyond immunotherapy** **Channel 1**
Moderation: E.G.E. De Vries¹, L. Siu², ¹Medical Oncology Department, UMCG - University Medical Center Groningen, Groningen, NL, ²Medical Oncology And Hematology Department, Princess Margaret Cancer Centre, Toronto, CA
- 13:00 - 13:15 **Assessing the microbiome: Tools for analysis and value as predictive factor to immunotherapy**
T. Gajewski, The University of Chicago, Chicago, US
- 13:15 - 13:30 **Pharmacology and lessons from non-cancer research**
M. Rescigno, Humanitas University, Milan, IT
- 13:30 - 13:45 **Patient selection for early phase clinical trials: What can the serum tell us about the gut microbiome?**
L. Derosa, Institut Gustave Roussy, Villejuif, FR
- 13:45 - 14:00 **“Bugs as drugs”: Using the microbiome to augment immunotherapy responses**
L. Siu, Princess Margaret Cancer Centre, Toronto, CA
- 14:00 - 14:15 **Live Q&A and discussion**
L. Siu¹, E.G.E. De Vries², T. Gajewski³, M. Rescigno⁴, L. Derosa⁵, ¹Princess Margaret Cancer Centre, Toronto, CA, ²UMCG - University Medical Center Groningen, Groningen, NL, ³The University of Chicago, Chicago, US, ⁴Humanitas University, Milan, IT, ⁵Institut Gustave Roussy, Villejuif, FR

- 13:00 - 14:15 Patient selection in phase I clinical trials** **Channel 2**
Moderation: E. Calvo¹, E. Garralda², ¹Dept. Early Clinical Drug Development, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ²Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 13:00 - 13:15 **Age, gender and other cofounders in early phase studies**
E. Garralda, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES
- 13:15 - 13:30 **Molecular profiling for target-based studies**
A. Stathis, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH
- 13:30 - 13:45 **Big data, Artificial Intelligence and clinical trials**
E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES
- 13:45 - 14:00 **MDICT update**
L. Seymour, Canadian Cancer Trials Group, Kingston, CA
- 14:00 - 14:15 **Live Q&A and discussion**
E. Calvo¹, E. Garralda², L. Seymour³, A. Stathis⁴, ¹Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ²Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Canadian Cancer Trials Group, Kingston, CA, ⁴EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

14:30 - 15:45 Multispecific biological constructs Channel 1

Moderation: M. Gutierrez¹, A. Tolcher², ¹The John Theurer Cancer Center, Hackensack, US, ²Clinical Research Director, NEXT Oncology™, San Antonio, US

14:30 - 14:45 **Multispecific IgM**

D.S. Chen, IGM Biosciences, Mountain View, US

14:45 - 15:00 **Multivalent DARPins**

M. Stumpp, Molecular Partners AG, Schlieren, CH

15:00 - 15:15 **Multispecific IgGs**

P. Umana, Roche Glycart AG, Schlieren, CH

15:15 - 15:30 **Recruitment and activation of the immune system**

M. Gutierrez, The John Theurer Cancer Center, Hackensack, US

15:30 - 15:45 **Live Q&A and discussion**

M. Gutierrez¹, A. Tolcher², D.S. Chen³, M. Stumpp⁴, P. Umana⁵, ¹The John Theurer Cancer Center, Hackensack, US, ²NEXT Oncology™, San Antonio, US, ³IGM Biosciences, Mountain View, US, ⁴Molecular Partners AG, Schlieren, CH, ⁵Roche Glycart AG, Schlieren, CH

14:30 - 15:45 Targeting and targeted cytokines Channel 2

Moderation: J. De Bono¹, I. Melero², ¹ICR - Institute of Cancer Research, London, GB,
²Laboratory Of Immunology, Clinica Universitaria de Navarra, Pamplona, ES

14:30 - 14:32 **Introduction**

I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

14:32 - 14:47 **Targeting chemokines and IL-23**

J. De Bono, ICR - Institute of Cancer Research, London, GB

14:47 - 15:02 **dsDNA targeted IL-12 and combinations cytokines**

M. Bilusic, Center for Cancer Research, Bethesda, US

15:02 - 15:17 **IL-6, TNF-alpha and IL-8**

I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

15:17 - 15:32 **Live Q&A and discussion**

J. De Bono¹, I. Melero², M. Bilusic³, J. Seoane⁴, ¹ICR - Institute of Cancer Research, London, GB, ²Clinica Universitaria de Navarra, Pamplona, ES, ³Center for Cancer Research, Bethesda, US, ⁴Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

15:32 - 15:47 **TGF-beta, LIF and extended families**

J. Seoane, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

- 16:00 - 17:00 Daiichi Sankyo - Innovative Antibody Engineering: Novel technologies and preclinical and clinical outcomes** **Channel 1**
Moderation: G. Curigliano, Early Drug Development for Innovative Therapies Division, European Institute of Oncology, Milan, IT
- 16:00 - 16:10 **Introduction**
G. Curigliano, European Institute of Oncology, Milan, IT
- 16:10 - 16:30 **Antibody engineering: Novel technologies, antibody drug conjugates and mechanisms of action**
M. Peipp, Christian-Albrechts-University, Kiel, DE
- 16:30 - 16:50 **Emerging preclinical and clinical data with novel antibody drug conjugates in various tumour types**
G. Curigliano, European Institute of Oncology, Milan, IT
- 16:50 - 17:00 **Q&A**
G. Curigliano¹, M. Peipp², ¹European Institute of Oncology, Milan, IT, ²Christian-Albrechts-University, Kiel, DE
- 16:00 - 16:20 Workshop Live Q&As in collaboration with the ESMO YOC: "How to assess response"** **Channel 2**
Moderation: L. Seymour¹, E. Calvo², E.G.E. De Vries³, P. Sobczuk⁴, ¹Ind Program, Canadian Cancer Trials Group, Kingston, CA, ²Dept. Early Clinical Drug Development, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ³Medical Oncology Department, UMCG - University Medical Center Groningen, Groningen, NL, ⁴ Warsaw, PL
- 16:00 - 16:20 **How to assess response**
N. Person, The Royal Marsden Hospital NHS Foundation Trust, London, GB
- 16:35 - 16:55 Workshop Live Q&As in collaboration with the ESMO YOC: "Challenges in conducting early clinical trials"** **Channel 2**
Moderation: R. Plummer¹, T. Yap², C. Oing³, R. Pihlak⁴, ¹Sir Bobby Robson Cancer Trials Research Centre, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ²Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, US, ³UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ⁴The Christie NHS Foundation Trust, Manchester, GB
- 17:15 - 18:15 Mini Oral session** **Channel 1**
Moderation: F. Thistlethwaite¹, G. Giaccone², ¹The Christie NHS Foundation Trust, Manchester, GB, ²Oncology, Weill Cornell Medicine, New York, US
- 17:15 - 17:20 **34MO - Outcomes according to FGFR alteration types in patients with a solid tumor treated by a pan-FGRF tyrosine kinase inhibitor in phase I/II trials.**
C. Pobel¹, F. Facchinetti¹, R. Bahleda¹, L. Verlingue¹, A. Gazzah¹, A. Varga¹, C. Baldini¹,

S. Champiat¹, A. Marabelle¹, M. Ningarhari¹, A. Geraud¹, Y. Loriot¹, C. Massard², J.-C. Soria¹, L. Friboulet², A. Hollebecque¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR

17:20 - 17:25 **35MO - Discovery and characterization of selective, FGFR1 sparing, inhibitors of FGFR2/3 oncogenic mutations for the treatment of cancers**

E. Dardenne¹, F. Padilla², S. Rasmussen¹, S.N. Yang¹, A. Mentès¹, L.S. Ogawa², R. Fiorenza¹, A. Trombino², S. Smith², D. Romashko¹, N. Ishiyama², M. Chevtsova², S. Thakur², E. Rosfjord¹, E. Buck¹, C. Roberts², M. Lucas², T.-A. Lin¹, ¹Black Diamond Therapeutics, New York, US, ²Black Diamond Therapeutics, Cambridge, US

17:25 - 17:30 **36MO - Safety, Tolerability and Preliminary Efficacy of Poziotinib with Twice Daily Strategy in EGFR/HER2 Exon 20 Mutant Non-small Cell Lung Cancer**

A. Sacher¹, X. Le², R. Cornelissen³, E. Shum⁴, M. Suga⁵, M. Socinski⁶, J. Molina⁷, E. Haura⁸, J. Clarke⁹, G. Bhat¹⁰, F. Lebel¹⁰, M. Garassino¹¹, ¹Princess Margaret Cancer Center, Toronto, CA, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Erasmus MC - University Medical Center, Rotterdam, NL, ⁴New York University Longone Health, New York, US, ⁵Vallejo Medical Center, Vallejo, US, ⁶Florida Hospital Cancer Institute, Orlando, US, ⁷Mayo Clinic, Rochester, US, ⁸Moffit Cancer Center, Tampa, US, ⁹Duke University, Durham, US, ¹⁰Spectrum Pharmaceuticals, Irvine, US, ¹¹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

17:30 - 17:40 **Invited discussant of abstracts 34MO, 35MO and 36MO**

M. Krebs, The Christie NHS Foundation Trust, Manchester, GB

17:40 - 17:45 **Live Q&A and discussion**

F. Thistlethwaite¹, D.S. Tan², C. Pobel³, E. Dardenne⁴, A. Sacher⁵, M. Krebs¹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ³Institut Gustave Roussy, Villejuif, FR, ⁴Black Diamond Therapeutics, New York, US, ⁵Princess Margaret Cancer Center, Toronto, CA

17:45 - 17:50 **8MO - CC-90010, a Reversible, Potent Oral Bromodomain and Extraterminal Inhibitor (BETi) in Patients (pts) with Advanced Solid Tumors (aSTs) and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Longer Follow-Up From Parts A & B and First Reporting of Part C of a Phase 1 Study**

V. Moreno¹, M. Vieito Villar², J. Sepulveda Sanchez³, V. Galvao⁴, T. Hernández Guerrero¹, B. Doger⁵, O. Saavedra⁶, C. Carlo Stella⁷, J.-M. Michot⁸, A. Italiano⁹, M. Magagnoli¹⁰, C. Carpio¹¹, R. Sarmiento¹², B. Amoroso¹³, I. Aronchik¹⁴, E. Filvaroff¹⁵, B. Hanna¹⁵, A. Pinto¹⁶, Z. Nikolova¹⁷, I. Braña², ¹University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³University Hospital 12 De Octubre, Madrid, ES, ⁴Vall d' Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ⁵START Madrid-FJD, Hospital Universitario Fundación Jimenez Diaz, Madrid, ES, ⁶Hospital Universitari Vall d'Hebron, Barcelona, ES, ⁷Humanitas Cancer Center, Humanitas Clinical and Research Center, Milan, IT, ⁸Institut Gustave Roussy, Villejuif, FR, ⁹Institut Bergonié, Bordeaux, FR, ¹⁰Humanitas Clinical and Research Center, Milan, IT, ¹¹Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital (HUVH), Barcelona, ES, ¹²Celgene Institute Translational Research Europe-CITRE, Sevilla, ES, ^{13a}



Bristol Myers Squibb Company, Seville, ES, ¹⁴Celgene, A Bristol-Myers Squibb Company, Summit, US, ¹⁵Bristol-Myers Squibb, Summit, US, ¹⁶Istituto Nazionale Tumori IRCSS Fondazione Pascale, Naples, IT, ¹⁷Celgene International Switzerland, Boudry, CH

- 17:50 - 17:55 **37MO - Concurrent mutations in STK11 and KEAP1 promote ferroptosis protection and SCD1 dependence in lung cancer**
T. Sen, Memorial Sloan Kettering Cancer Center, New York, US
- 17:55 - 18:00 **38MO - IND.236: A Canadian Cancer Trial Group (CCTG) Phase 1b trial of combined CFI-402257 and weekly paclitaxel (Px) in patients with HER2-negative (HER2-) advanced breast cancer (BC)**
M. Mates¹, P. Bedard², J. Hilton³, K. Gelmon⁴, A. Srikanthan³, A. Awan³, X. Song³, C. Lohrisch⁴, A. Robinson¹, D. Tu⁵, L. Hagerman⁵, S. Zhang⁶, N. Drummond-Ivars³, I. Li², L. Rastgou⁴, J. Edwards¹, M. Bray⁷, M. Rushton⁸, P.-O. Gaudreau⁶, ¹Cancer Centre of Southeastern Ontario, Kingston, CA, ²Princess Margaret Cancer Center, Toronto, CA, ³The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ⁴BC Cancer Agency - Vancouver, Vancouver, CA, ⁵Canadian Clinical Trials Group, Kingston, CA, ⁶Queen's University, Kingston, CA, ⁷UHN, Toronto, CA, ⁸Canadian Cancer Trials Group, Kingston, CA
- 18:00 - 18:10 **Invited discussant of abstracts 8MO, 37MO and 38MO**
S. Galbraith, AstraZeneca - IMED Biotech, Cambridge, GB
- 18:10 - 18:15 **Live Q&A and discussion**
F. Thistlethwaite¹, D.S. Tan², V. Moreno³, T. Sen⁴, M. Mates⁵, S. Galbraith⁶, ¹The Christie NHS Foundation Trust, Manchester, GB, ²NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG, ³University Hospital "Fundacion Jimenez Diaz", Madrid, ES, ⁴Memorial Sloan Kettering Cancer Center, New York, US, ⁵Cancer Centre of Southeastern Ontario, Kingston, CA, ⁶AstraZeneca - IMED Biotech, Cambridge, GB
- 18:30 - 18:50 Take home messages and close Channel 1**
Moderation: R. Plummer¹, L. Seymour², ¹Sir Bobby Robson Cancer Trials Research Centre, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ²Ind Program, Canadian Cancer Trials Group, Kingston, CA
- 18:30 - 18:48 **Live TAT 2021 highlights**
P. Bedard, Princess Margaret Cancer Center, Toronto, CA
- 18:48 - 18:50 **Live congress closure**
R. Plummer¹, L. Seymour², ¹The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ²Canadian Cancer Trials Group, Kingston, CA